-Reuters
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits In Severe Alzheimer’s Disease Accepted For Presentation At 11th International Brain Research Organization World Congress Of Neuroscience
Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation
NEW YORK, July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX)